Invectys raises 1.7 million Euros more to finance the clinical development of its therapeutic cancer vaccine With a total of 10 million euros raised, new premises,…
Invectys Initiates Phase I Clinical Trial Evaluating INVAC-1 Therapeutic Vaccine for Cancer Patients A new clinical hope in cancer immunotherapy Paris, May 12th,…
Invectys receives ANSM approval to start clinical trial for INVAC-1, its leading anticancer immunotherapy INVAC-1 is an anticancer candidate vaccine targeting…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
Invectys focuses on the development of innovative anti-cancer therapeutic approaches in immunotherapy. It is backed by French and international private investors…
A new clinical hope in cancer immunotherapy Paris, May 12th, 2015 – Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic…
Anti-cancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Thalmensi, J., Pliquet, E.,…
